Uncompromising Commitment to Future Medicine
By integrating medical, biological, and analytical excellence, Transgenion develops tools for precision medicine against the most challenging Chronic Inflammatory Diseases (CIDs) of advanced age.
Important Milestones in our progress to Personalized Medicine
By integrating extensive medical and biomolecular research over two decades, Transgenion has developed a revolutionary set of clinically validated biomarkers. These markers serve as targets for Chronic Obstructive Pulmonary Disease (COPD), one of the leading CIDs in the world.
Development of Vienna COPD Study concept
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Development of RESOLVE
Organ Fibrosis: Secondary repair with/without inflammation
Development of RESOLVE study concept allowing for the systematic comparison of Wound healing and Chronic inflammation in 26 clinically relevant CID plus/minus organ fibrosis.
Successful Funding
COPD Target Identification Clinical-Molecular Profiling Pilot trial
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Study System for comparing wound healing & inflammation with/without organ fibrosis
Development of RESOLVE study concept allowing for the systematic comparison of Wound healing and Chronic inflammation in 26 clinically relevant CID plus/minus organ fibrosis.
Founding Transgenion
Granting 25 patents for COPD in the EU, US and Japan.
The list of all patents, including links, can be found on our Investors Relations page.
Investors Relation
Prof. Dr. Rolf Ziesche
Inventor, Founder & CEO
